Trial Profile
Real world study to assess comparative rates of clinical cure, mortality, and acute kidney injury (AKI) among patients treated with Ceftolozane/Tazobactam versus a Polymyxin or Aminoglycoside based regimen for P. aeruginosa infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2018
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Therapeutic Use
- 18 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018